Status:
RECRUITING
Oral Ketamine for Treatment of Vaso-Occlusive Pain
Lead Sponsor:
Boston Children's Hospital
Conditions:
Vaso-occlusive Crisis
Eligibility:
All Genders
12-24 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to learn more about the feasibility of oral ketamine for the treatment of painful sickle-cell crises in children and adolescents as a supplement to intravenous (IV) opioid...
Detailed Description
This is a pilot study of the feasibility of oral ketamine dosing initiated in the Emergency Department and continued for 48 hours for adolescents and young adults hospitalized with VOCs. A total of 10...
Eligibility Criteria
Inclusion
- Patients 12-24 years of age who require admission for vaso-occlusive pain
Exclusion
- Patients who have had side effects to previous use of intravenous ketamine for treatment of vaso-occlusive pain that would preclude using ketamine for future pain episodes.
- Patient refusal to participate
Key Trial Info
Start Date :
May 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT05378555
Start Date
May 1 2023
End Date
June 1 2026
Last Update
November 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Boston Children's Hospital
Boston, Massachusetts, United States, 02115